iCAD (NASDAQ:ICAD) Stock Rating Lowered by StockNews.com

iCAD (NASDAQ:ICAD) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

iCAD Stock Down 23.7 %

NASDAQ ICAD opened at $1.79 on Wednesday. iCAD has a 52 week low of $1.18 and a 52 week high of $2.65. The business has a 50 day moving average price of $1.70 and a 200-day moving average price of $1.54. The company has a market cap of $47.37 million, a price-to-earnings ratio of -16.91 and a beta of 1.47.

iCAD (NASDAQ:ICAD) last announced its quarterly earnings results on Tuesday, August 13th. The technology company reported ($0.07) EPS for the quarter. iCAD had a negative net margin of 15.67% and a negative return on equity of 13.59%. The business had revenue of $5.03 million for the quarter.

Hedge Funds Weigh In On iCAD

Large investors have recently added to or reduced their stakes in the business. First Eagle Investment Management LLC raised its stake in shares of iCAD by 3.2% in the first quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock worth $1,129,000 after purchasing an additional 22,000 shares during the last quarter. Perritt Capital Management Inc. grew its holdings in iCAD by 7.5% during the first quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock worth $225,000 after buying an additional 9,717 shares in the last quarter. Virtu Financial LLC raised its position in iCAD by 55.6% in the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after buying an additional 7,604 shares during the last quarter. Perritt Capital Management Inc lifted its stake in iCAD by 14.2% during the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after acquiring an additional 19,917 shares in the last quarter. Finally, Essex LLC purchased a new position in iCAD during the 3rd quarter worth $216,000. Institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.